Oct. 25 (Bloomberg) -- Amsterdam Molecular Therapeutics NV plans to cut its workforce by half to 45 full-time employees and suspended the development program of its main product Glybera as further investment is no longer tenable, the company said in a statement today on its website.

To contact the editor responsible for this story: Fred Pals at fpals@bloomberg.net